Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $12.27, for a total transaction of $24,540.00. Following the transaction, the president now directly owns 2,932,467 shares of the company’s stock, valued at approximately $35,981,370.09. This trade represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Songjiang Ma also recently made the following trade(s):

• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total value of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total value of $22,100.00.

Gyre Therapeutics Price Performance

Shares of Gyre Therapeutics stock traded up $1.23 during midday trading on Thursday, reaching $13.13. 154,470 shares of the company’s stock traded hands, compared to its average volume of 75,219. The stock has a 50 day moving average of $12.76 and a 200-day moving average of $12.62. Gyre Therapeutics, Inc. has a 12 month low of $8.26 and a 12 month high of $28.79.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at about $218,000. Rhumbline Advisers purchased a new stake in Gyre Therapeutics in the second quarter worth about $123,000. WINTON GROUP Ltd purchased a new stake in Gyre Therapeutics in the second quarter worth about $220,000. Renaissance Technologies LLC bought a new stake in Gyre Therapeutics during the 2nd quarter valued at approximately $166,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after acquiring an additional 90,557 shares during the period. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.